Skip to content
Blerp – Lifestyle
Author:
Vector Sciences & Therapeutics
Verlytix Launches as a Related Company to LyoGenesis Manufacturing
August 18, 2026
Vector Science and Therapeutics Corp. Signs Amended, 10-Year Manufacturing and Testing Agreement with LyoGenesis Holdings
August 17, 2026
Vector Science & Therapeutics Corp., LyoGenesis Plus and Wynn Pharmaceuticals Announce Strategic Collaboration to Develop and Manufacture Critical Care Medical Products
July 28, 2026
Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28
July 24, 2026
Vector Science & Therapeutics Announces Distributor Network Buildout to Support Its Peptide Portfolio Across Orthopedic, Sports, and Regenerative Medicine Channels
July 21, 2026
Vector Science & Therapeutics and Caresyntax Announce Real-World Evidence Partnership for VectorMist
July 17, 2026
Vector Science & Therapeutics Builds 15-Patent-Application Intellectual Property Portfolio Around Precision Therapeutic Delivery, Anchored by Peptide and Biologic Administration Technologies
July 15, 2026
Vector Science & Therapeutics Announces Landmark Exclusive cGMP Manufacturing Agreement with LyoGenesis Plus for Its Proprietary Peptide Portfolio
July 7, 2026
Vector Science & Therapeutics Files Provisional Patent for Breakthrough Transdermal Peptide Delivery Platform
June 30, 2026
Gary Payton II Named Chief Athletic Ambassador of Valor
June 22, 2026
1
2
Next Page
→